The European LeukemiaNet (ELN) criteria define the adverse genetic factors of acute
myeloid leukemia (AML). AML with adverse genetic factors uniformly shows resistance to …

Ameloblastoma is an odontogenic neoplasm characterized by slow intraosseous growth
with progressive jaw resorption. Recent reports have revealed that ameloblastoma harbours …

Introduction: Multiple myeloma (MM) is a hematologic malignancy characterized by
proliferation of malignant plasma cells. patient outcome has improved markedly over the last …

Pan-RAF inhibitors have shown promise as antitumor agents in RAS and RAF mutated solid
cancers. However, the efficacy of pan-RAF inhibitors in acute myeloid leukemia (AML) has …

RAS mutations occur frequently in multiple myeloma (MM), but apart from driving
progression, they can also stimulate antitumor effects by activating tumor-suppressive …

Experimental data on resistance mechanisms of multiple myeloma (MM) to ixazomib (IXA), a
second-generation proteasome inhibitor (PI), are currently lacking. We generated MM cell …

Our previous research had firstly shown that MM cells overexpressed IQGAP1 gene and
activated Ras/Raf/MEK/ERK pathway. But the mechanism of IQGAP1 overexpression and …

A major driver of multiple myeloma (MM) is thought to be aberrant signaling, yet no kinase
inhibitors have proven successful in the clinic. Here, we employed an integrated, systems …

Oncogenic RAS provides crucial survival signaling for up to half of multiple myeloma (MM)
cases, but has so far remained a clinically undruggable target. RAS-like protein (RAL) is a …

Lung cancer is the leading cause of cancer-associated mortality worldwide and its prognosis
is poor. Few effective biomarkers for non‑small cell lung cancer (NSCLC) have been …